Multimodal imaging based on MRI and PET reveals [18F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma
Multimodal imaging based on MRI and PET reveals [18F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma
复制标题
DOI：
10.1007/s00259-015-3225-0
复制
发表时间：
2016-04-01
影响因子：
9.1
通讯作者：
Valable, Samuel
中科院分区：
文献类型：
--
作者：
Corroyer-Dulmont, Aurelien;Peres, Elodie A.;Valable, Samuel
本研究的主要目的是比较PET和MRI生物标志物在复发性多形性胶质母细胞瘤临床前模型中预测治疗效果的能力。（解剖学，扩散，血管和氧合）和PET在治疗结束后3天获得[F-18]FDG和[F-18]FLT参数，并与晚期肿瘤生长和生存进行比较。通过T2-WMRI评估，未观察到替莫唑胺联合贝伐单抗治疗对肿瘤体积的影响。后来，治疗减少了肿瘤体积并提高了生存率。有趣的是，在早期，替莫唑胺+贝伐珠单抗降低[F-18]FLT摄取、脑血容量和水肿。[F-18]FLT摄取，水肿和脑血容量与总生存率相关，但[F-18]FLT摄取具有最高的特异性和敏感性的早期预测治疗effictiveness.Conclusion目前的调查在胶质母细胞瘤复发的临床前模型强调了多模态成像在水肿，肿瘤血管状态和细胞增殖的评估的重要性。最后，[F-18]FLT在治疗效果的早期评估方面具有最大的前景。这些研究结果可能会转化为临床上的复发性胶质瘤的个性化治疗，可以为PET/MRI检查后选择的患者开处方。
Purpose The primary objective of this study was to compare the ability of PET and MRI biomarkers to predict treatment efficacy in a preclinical model of recurrent glioblastoma multiforme.Methods MRI (anatomical, diffusion, vasculature and oxygenation) and PET ([F-18]FDG and [F-18]FLT) parameters were obtained 3 days after the end of treatment and compared with late tumour growth and survival.Results Early after tumour recurrence, no effect of treatment with temozolomide combined with bevacizumab was observed on tumour volume as assessed by T2-W MRI. At later times, the treatment decreased tumour volume and increased survival. Interestingly, at the earlier time, temozolomide + bevacizumab decreased [F-18]FLT uptake, cerebral blood volume and oedema. [F-18]FLT uptake, oedema and cerebral blood volume were correlated with overall survival but [F-18]FLT uptake had the highest specificity and sensitivity for the early prediction of treatment efficacy.Conclusion The present investigation in a preclinical model of glioblastoma recurrence underscores the importance of multimodal imaging in the assessment of oedema, tumour vascular status and cell proliferation. Finally, [F-18]FLT holds the greatest promise for the early assessment of treatment efficacy. These findings may translate clinically in that individualized treatment for recurrent glioma could be prescribed for patients selected after PET/MRI examinations.